Strides Pharma Science share news, announcements and annual reports
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Strides Pharma Science Limited · Formerly Strides Shasun · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000 on NSE, Jun 2004 on BSE
Last close ₹1,036.90down ₹31.90 (2.98%)BSE ₹1,037.80
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,068.80.
2 Nov: open ₹1,067.30, high ₹1,067.30, low ₹1,013.90
52-week range of traded prices to 2 Nov 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,557 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 15.50
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.80
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.48%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,07,98637.7% delivered
Strides Pharma Science share news and announcements
1,447 announcements, routine notices left out, newest first. Page 25 of 29.
Aug 2010
2 Aug · Business
Company has allotted 100,500 fully paid equity shares of Rs. 10/- each under Strides Arcolab ESOP 2008 Scheme. Consequent to the allotment, the paid up equity share capital of the Company has increased from Rs. 435,391,380 consisting of 43,539,138 equity shares of Rs. 10/ each to Rs. 436,396,380 consisting of 43,639,638 equity shares of Rs. 10/- each.
Jul 2010
27 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 11861.9 lacs for quarter ending on 30-JUN-2010 against Rs. 17540.67 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. (1358.82) lacs for the quarter ending on 30-JUN-2010 against Rs. 6012.61 lacs for the quarter ending on 30-JUN-2009.27 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 45446.57 lacs for quarter ending on 30-JUN-2010 against Rs. 30975.54 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 4575.65 lacs for the quarter ending on 30-JUN-2010 against Rs. 4177.03 lacs for the quarter ending on 30-JUN-2009.20 Jul · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended June 30, 2010.
Jun 2010
28 Jun · Meeting
Company will convene an Extra-ordinary General Meeting (EGM) on July 23, 2010, to seek shareholders approval for the following: (1) Increase in borrowing powers from Rs.1500 crores to Rs.2500 Crores; (2) Raising of funds upto USD 100 Million through issue of GDRs/ ADRs/ FCCBs/ QIP/ such other equity linked instruments etc.18 Jun · Change in Company Secretary
Mr. Badree Komandur has been appointed as "Company Secretary", in place of Mr. Kannan. N. Further, Mr. Badree Komandur shall also act as the Compliance Officer of the Company.15 Jun · Disclosure
Compensation Committee of the Company has granted 100,000 options to an eligible employee under the Strides Arcolab ESOP 2008 Scheme at Rs. 311.40 per option (exercise price). The shares covered by such options are 100,000 shares. The vesting period of these options is in a phased manner over a period of 3 years. The options may be exercised within a period of 30 days from the date of vesting.
May 2010
26 May · Business
Company has allotted 10,000 fully paid equity shares of Rs. 10/- each under Strides Acrolab ESOP 2008 (Director) Scheme to a Director of the Company. Consequent to the allotment, the paid up Equity share capital of the Company has increased from Rs. 435,291,380 consisting of 43,529,138 equity shares of Rs. 10/- each to Rs. 435,391,380 consisting of 43,539,138 equity shares of Rs. 10/- each.19 May · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended March 31,2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 May · Meeting
Register of Members and Transfer Books of the Company will remain closed from May 25, 2010 to May 31, 2010 (both days inclusive), in connection with the Annual General Meeting of the Company convened to be held on May 31, 2010 and for the purpose of payment of dividend on equity shares for the year ended December 31, 2009, if declared and authorised at the ensuing AGM of the Company.
Apr 2010
23 Apr · Allotment of Equity Shares
Company has allotted 320,000 fully paid equity shares of Rs.10/- each under various ESOP Scheme of the Company. Consequent to the allotment, the paid up equity share capital of the Company has increased from Rs. 432,091,380 consisting of 43,209,138 equity shares of Rs. 10/- each to Rs. 435,291,380 consisting of 43,529,138 equity shares of Rs.10/- each.22 Apr · Business
Press release dated April 22, 2010 titled "Strides today announced Q1'10 financials; Delivers strong growth and Performance is in line with guidance". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 13138.78 lacs for quarter ending on 31-MAR-2010 against Rs. 16975.82 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 1006.45 lacs for the quarter ending on 31-MAR-2010 against Rs. 2148.14 lacs for the quarter ending on 31-MAR-2009.22 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 37355.06 lacs for quarter ending on 31-MAR-2010 against Rs. 28425.77 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 3983.01 lacs for the quarter ending on 31-MAR-2010 against Rs. 1048.18 lacs for the quarter ending on 31-MAR-2009.22 Apr · Business
Press release dated April 22, 2010, titled "Strides Arcolab Announces US FDA Tentative Approval of Additional Adenosine Injection; Approval Momentum Continues - Total Approvals in Sterile Space at 23". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Apr · Business
Press release dated April 21, 2010 , titled "Strides Arcolab Announces USFDA Approval For Metoprolol Tartrate Injection; Approval Momentum Continues - Total Approvals in Sterile Space AT 22". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Apr · Business
Press release dated April 20, 2010 , titled "Strides redeems USD 34 Million FCCBs due 2010". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Apr · Business
Press release dated April 19, 2010, titled "Strides Arcolab announces USFDA approval for Mesna Injection- Total Approvals In Sterile Space At 21". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Apr · Business
Press release dated April 14, 2010, titled "Strides Arcolab announces USFDA approval for Granisetron Hydrochloride Injection - Total Approvals in Sterile Space at 20". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Apr · Board meeting
Meeting on 22 Apr 2010: “Unaudited Financial Results for the qtr ended March 31, 2010”
Mar 2010
31 Mar · Legal
"Clarification on Pharmabiz.com article dated March 31, 2010 - on expired drugs issue in Tamil Nadu." The details of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Mar · Business
Press release dated March 18, 2010, titled "Strides revises guidance upwards for FY 2010 ; Post Oncology and Campos transactions with Aspen". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Mar · Business
Press release dated March 18, 2010, titled "Strides and Aspen restructure Oncology arrangements, Strides to acquire 100% interest in Oncology JVs". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Mar · Allotment of Equity Shares
Company has allotted 420,000 fully paid equity shares of Rs. 10/- each against conversion of 420,000 warrants at a price of Rs. 91.15 per share to the entity/ persons belonging to the promoter group. (as per attachment) Consequent to the allotment, the paid up equity share capital of the Company has increased from Rs. 427,891,380 consisting of 42,789,138 equity shares of Rs. 10/- each to Rs. 432,091,380 consisting of 43,209,138 equity shares of Rs. 10/- each. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Mar · Business
Press release dated March 16, 2010, titled "Proposal for Acquisition of Minority Shares in Ascent Pharmahealth Ltd ". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Mar · Business
Press release dated March 04, 2010, titled " Strides to acquire Campos facility in Brazil from Aspen". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2010
24 Feb · Allotment of Equity Shares
The Company has allotted 2,560,000 fully paid equity shares of Rs. 10/- each against conversion of 25,60,000 warrants at a price of Rs. 91.15 per share to Netequity Ventures Private Limited, a promoter group company. Consequent to the allotment, the paid up equity share capital of the Company has increased from Rs. 402,291,380 consisting of 40,229,138 equity shares of Rs. 10/- each to Rs. 427,891,380 consisting of 42,789,138 equity shares of Rs. 10/- each24 Feb · Updates
Details as per requirement of clause 20 of the listing Agreement. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Feb · Business
Press release dated February 24, 2010 with respect to the Audited Financial Results for the year ended December 31, 2009. Further the Company has submitted a copy of Results Pack Financials for the year 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Feb · Dividend
Board of Directors of the Company at their meeting held on February 24, 2010 has recommended dividend at 15% viz., Rs.1.50/- per share for the year ended December 31, 2009.24 Feb · Results
Standalone Results for the year ended on 31-DEC-2009 as follows: Net Sales of Rs. 76944.2 lacs for year ending on 31-DEC-2009 against Rs. 59313.75 lacs for the year ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 10551.43 lacs for the year ending on 31-DEC-2009 against Rs. 613.46 lacs for the year ending on 31-DEC-2008.24 Feb · Results
Consolidated Results for the year ended on 31-DEC-2009 as follows: Net Sales of Rs. 130477.14 lacs for year ending on 31-DEC-2009 against Rs. 102033.1 lacs for the year ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 10968.39 lacs for the year ending on 31-DEC-2009 against Rs. 10796.38 lacs for the year ending on 31-DEC-2008.15 Feb · Board meeting
To consider inter-alia, the audited financial results of the Company for the financial year ended December 31, 2009 and recommendation of dividend, if any.